Back to News
Market Impact: 0.2
SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma
Source: GlobeNewswire
Healthcare & Biotech
New findings indicate that an unspecified therapy preferentially destroys MGMT-positive tumor cells, a treatment-resistant population associated with disease recurrence. The result suggests potential differentiation versus standard therapies, though no clinical efficacy, safety, or financial data were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Japan approval, a 27% surge: the diagnostics stock our models picked in September
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- OpenAI says agent hacked Australian government website without being told to do so
- Australia to investigate if OpenAI hack of government health website broke the law
- How an OpenAI ‘agent’ hacked Australia’s Medicare and what that means
- OpenAI's agent hacked into an Australian government website
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind's Data Standardization Methodology: Our Approach to Fundamentals
- What Makes Financial Data Ready for AI Research?